Message

From: Culleen, Lawrence E. [Lawrence.Culleen@arnoldporter.com]

Sent: 8/21/2020 9:44:48 PM

To: Stanley, Darrell [stanley.darrell@epa.gov]

CC: Dekleva, Lynn [dekleva.lynn@epa.gov]; Henry, Tala [Henry.Tala@epa.gov]

Subject: as discussed.

Attachments: Stanley 082120.pdf

Darrell ---

Here is a letter requesting a discussion and further guidance on the "in-scope" decision making processes for PAG substances that are reported in new PMNs. As we have discussed, the PAG Consortium members continue to think there would be value gained by scheduling a meeting soon, to enable a small cadre of the PAG Consortium's "technical team" members to confer with their counterparts in RAD. During such a meeting, we would like to learn more about the Agency's decision making process and collaboratively: (a) share perspectives on the kinds of information that might be avaible to assist EPA personnel in making such determinations; and (b) exchange insights based on recent experiences gained in the few months since the initial group of Section 5(e) Consent Orders were signed.

The Consortium's technical team members generally are available at 3 pm eastern on Thursdays. Perhaps that time also would work for you and a small group of your colleagues who are engaged in the pertinent process. I will contact you soon to follow-up and look for mutually convenient dates.

As a courtesy and for the sake of continuity, I am copying Tala and Lynn; unfortunately, due to recent personnel changes, I am not certain of others in the OCSPP management chain who also have an interest in this topic.

As always, I look forward to speaking again soon.

Larry

Lawrence Culleen
Partner

Arnold & Porter
601 Massachusetts Ave., NW
Washington | District of Columbia 20001-3743
T: +1 202.942.5477

Lawrence.Culleen@arnoldporter.com | www.arnoldporter.com

To help our clients navigate the coronavirus (COVID-19) crisis, Arnold & Porter has established a <u>Task Force</u> covering a wide range of issues and challenges. <u>Subscribe</u> to our "Coronavirus (COVID-19)" mailing list to receive our latest client Advisories and Webinars on the topic.

This communication may contain information that is legally privileged, confidential or exempt from disclosure. If you are not the intended recipient, please note that any dissemination, distribution, or copying of this communication is strictly prohibited. Anyone who receives this message in error should notify the sender immediately by telephone or by return e-mail and delete it from his or her computer.